Form 4: Elevation Oncology CEO Joseph Ferra Jr. Reports Stock Transactions
SEC Form 4 Filing
CEO Joseph Ferra Jr. reports the vesting of restricted stock units and subsequent tax withholding of shares.
Summary
- On June 16, 2024, Joseph Ferra Jr., CEO of Elevation Oncology, Inc., reported transactions involving the company's common stock.
- Specifically, 12,562 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of Elevation Oncology's common stock.
- Following the vesting, Ferra disposed of 4,628 shares to cover tax obligations at a price of $3.23 per share.
- After these transactions, Ferra directly owns 93,614 shares of common stock and 50,247 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by an insider, with no inherently positive or negative implications.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency to the market about insider activity.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect compensation-related activities.
Key Dates
| Date | Description |
|---|---|
| 06/16/2022 | 25% of the RSUs vested. |
| 06/16/2024 | Date of reported transactions: vesting of RSUs and tax withholding. |
| 06/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.